Authors:

Miroslav Malkovsky

University in Madison, Wisconsin, USCorrespondence to Author: Miroslav Malkovsky

Abstract:

The pandemic spread of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires very urgently to identify effective therapies and prophylaxis. This appears perhaps even more imperative, after remdesivir, seemingly the most promising antiviral drug with very potent in vitro activity against SARS-CoV-2, was tested in adults with severe COVID-19 in a randomized, double-blind, placebo-controlled, multi-centre trial with somewhat disappointing results [1] (quote): “In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits.” ” Therapeutic Plasma Exchange (TPE) is an effective treatment in many clinical situations and a typical single TPE treatment takes about 2 hours and replaces 1 to 1.5 blood volumes; the plasma is discarded and replaced by an isotonic solution of ~5% human albumin, which typically…

Keywords:

TPE-Nabs, Combination Therapy, Severe COVID-19

Citation:

Miroslav Malkovsky. TPE-Nabs Combination Therapy for Severe COVID-19. World Journal of Medical Oncology 2020.